After certifying in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at Dana-Farber Cancer Institute (DFCI), Prof Paul Richardson joined the Jerome Lipper Myeloma Center in 1999, was appointed Clinical Director in 2001, and led the development of several first-generation novel drugs including bortezomib, lenalidomide and pomalidomide. Subsequent studies have focused on next generation novel drugs including histone deacetylase inhibitors such as panobinostat and other small molecules including the second-generation proteasome inhibitors NPI 0052 (also known as marizomib) and MLN 9708 (now known as ixazomib), with the goal of further improving patient outcomes. More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma.
Previously, his senior investigator role in the VISTA trial comparing bortezomib in combination with melphalan and prednisone versus melphalan and prednisone alone as part of an international Phase 3 trial established bortezomib, melphalan and prednisone (VMP) as a new treatment standard in multiple myeloma patients not eligible for stem cell transplant. At present, his major effort has been focused on the Intergroup Francophone Myelome (IFM)/DFCI clinical trial in newly diagnosed patients eligible for stem cell transplant treated with lenalidomide, bortezomib and dexamethasone (RVD). This regimen has generated an unprecedented response rate, leading to its adoption in this international study (as well as in the United States and elsewhere), which incorporates genomic and proteomic evaluation to establish a future platform for tailored therapy.
Other important contributions include the management of treatment-emergent neuropathy in myeloma. Similarly, the development of defibrotide for the treatment and prevention of hepatic veno-occlusive disease following stem cell transplantation has been aimed at improving therapeutic outcome, with defibrotide emerging as the first agent approved for this unmet medical need.
Prof Richardson has published extensively, having authored or co-authored more than 360 original articles and 280 reviews, chapters, and editorials in peer-reviewed journals. In addition to holding positions on the Editorial Boards of leading journals, he is prior Chairman of the Multiple Myeloma Research Consortium (MMRC), Clinical Trials Core, a position held for 5 years as part of a rotating tenure, and for which he continues as a member of the Steering and Project Review Committee. He was also a member of ASCO Hematologic Malignancies Subcommittee for the required one-year term, and then for one year on the ASCO Internet Cancer Information Committee during 2017. He was appointed Chair of the Alliance Myeloma Committee in 2011 and continues in this role.
Honors include the George Canellos Award for Excellence in Clinical Research and Patient Care, The Tisch Outstanding Achievement Award for Clinical Research and an honorary Fellowship of the Royal College of Physicians (UK), given in recognition for international contributions in multiple myeloma and stem cell transplantation. He was a co-recipient of the prestigious Warren Alpert Foundation Prize in recognition of the successful therapeutic targeting of the ubiquitin-proteasome pathway. He was a co-recipient of the Accelerator Award for contributions to clinical research and patient enrollment in MMRC studies, as well as for the Research Center of the Year Award in 2009, followed by a second award for Center of the Year in 2017. He was ranked by Thomson Reuters Science Watch amongst the top 19 investigators at DFCI for the most highly cited research in 2016. Most recently, he was the co-recipient of the ASH Ernest Beutler Prize for clinical science and translational research in the development of proteasome inhibition as an effective treatment strategy for multiple myeloma in 2015; the COMY Award for MM research (Paris, France) in 2016, and the IMF Robert A. Kyle Lifetime Achievement Award in 2017.
Dr Jesus San-Miguel is Professor of Medicine (Haematology) and Director of Clinical and Translational Medicine at the University of Navarra. He served as director of the Hematology Department of the University Hospital of Salamanca for over 22 years (1991-2013).
His interest in multiple myeloma bagan with his Ph.D. thesis in the early 1980s and has since devoted most of his time on improving our understanding in the biology, prognosis and therapeutics of this disease. He has published over 775 papers in the top journals including Blood, JCO, NEJM and Lancet Oncology.
Prof San Miguel is President of the International Myeloma Society, member of the Academy of Pharmacy of Castilla-León and the Royal Academy of Medicine of Salamanca, as well as member of the Advisory Board of the International Myeloma Foundation, the Multiple Myeloma Research Foundation, Carreras Foundation. He has served on the Boards of the Spanish Hematology Association, European Hematology Association and Genome Foundations. Among others, he is Associate Editor of Blood and he also was Associated Editor of Haematologica. He has received numerous prizes including the Michaeli Award for his contribution to Myeloma, the Waldenström Award, the Kyle Life Achievement Award, the EHA "Jose Carreras" Award, the Rey Jaime I on Medical Research Award and the Spanish prizes on both Oncology and Translational Research.
Professor Andrew Spencer is Head of the Malignant Haematology and Stem Cell Transplantation Service at The Alfred Hospital, Professor of Haematology at Monash University and Head of the Myeloma Research Group and Co-Director of the ACRF Blood Cancer Therapeutics Centre at the Australian Centre for Blood Diseases - all in Melbourne, Australia.
Prof Spencer completed his medical training in clinical and laboratory haematology in Brisbane and Sydney in 1992. He then was awarded a LRF (UK) Fellowship and spent 3 years at The Royal Postgraduate Medical School, London, United Kingdom where he undertook research into B-cell clonality in chronic myeloid leukemia and was awarded a Doctorate in Medicine from the University of London.
Subsequently he moved to The Alfred Hospital where he established an independent translational research program. He was appointed Head of Malignant Hematology and Stem Cell Transplantation Services in 2007 and established a first-in-human and early phase hematology clinical research unit at the hospital in 2009. He has more than 185 peer-reviewed publications with citations in excess of 12,600, and holds 4 international patents in multiple myeloma (MM) therapeutics.
He has been an invited speaker at 40 international meetings on genomics, therapeutics and disease monitoring in MM and is an invited investigator of the International Myeloma Foundation (IMF) Black Swan Research Initiative devising and implementing global minimal residual disease strategies for MM.
He serves on the scientific advisory boards of the IMF and the International Myeloma Working Group and Chairs the Myeloma and Related Diseases Registry that he established in 2012 and the Australasian Myeloma Research Consortium. He also sits on the steering committee for the global MM registry initiative INSIGHT.
Professor David Gottlieb trained in medicine at Sydney and Westmead Hospitals. He completed a doctorate in Medicine at the Royal Free Hospital in London before returning to Australia in 1990 to take up an academic position with the University of Sydney, where he is currently Professor of Haematology.
He is BMT Program Director and Director of Cell Therapies at Westmead Hospital. His major research interest is in cellular immunotherapy for the treatment of infection and malignancy in immunocompromised patients especially in allogeneic stem cell transplant recipients and focuses on adoptive immunotherapy for rapid reconstruction of the immune system following intensive therapy. He has been principal investigator or multiple trials of pathogen specific T cells and is a lead investigator on preclinical and clinical trials of CD19 CAR T cells currently being run at Westmead Hospital.
He is past President of the Haematology Society of Australia and New Zealand and currently President of the Bone Marrow Transplant Society of Australia and New Zealand.